ADAMTS13 Improving the Cell Engraftment Efficacy in Mouse Model of Bone Marrow Transplantation

被引：0
|
作者：
Matsui, Hideto [1 ]
Doi, Masaaki [1 ]
Matsunari, Yasunori [1 ]
Takeda, Maiko [1 ]
Nishio, Kenji [1 ]
Shima, Midori [1 ]
Soejima, Kenji [2 ]
Banno, Fumiaki [3 ]
Akiyama, Masashi [3 ]
Kokame, Koichi [3 ]
Miyata, Toshiyuki [3 ]
Sugimoto, Mitsuhiko [1 ]
机构：
[1] Nara Med Univ, Kashihara, Nara 634, Japan
[2] Chemoserotherapeut Res Inst, Res Dept 1, Kumamoto, Japan
[3] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1077.1077
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1077
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Determination of the Level of von Willebrand Factor, ADAMTS13, and Ratio of ADAMTS13:von Willebrand Factor in Sickle Cell Disease Patients
    Onorhide, Akaba
    Idongesit, Akpan
    Olanrewaju, Osho
    ANNALS OF AFRICAN MEDICINE, 2025, 24 (01) : 124 - 145
  • [42] ADAMTS13/vWF Regulates the Efficacy of tPA in Ischemic Stroke Patients
    Deng Wenjun
    Liu, Kai
    Fisher, Lindsay
    Chou, Richard
    Bunda, Bridget
    Wang, Andrew
    D'Souza, Erica
    McMullin, David
    Buonanno, Ferdinando
    Ferdinando, Lo
    Eng, H.
    Ning MingMing
    STROKE, 2019, 50
  • [43] Donor-origin cell engraftment after intraosseous or intravenous bone marrow transplantation in a rat model
    Klimczak, A.
    Unal, S.
    Jankowska, A.
    Coburn, C.
    Siemionow, M.
    BONE MARROW TRANSPLANTATION, 2007, 40 (04) : 373 - 380
  • [44] Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease
    Rossato, Paolo
    Glantschnig, Helmut
    Canneva, Fabio
    Schuster, Maria
    Coulibaly, Sogue
    Schrenk, Gerald
    Voelkel, Dirk
    Dockal, Michael
    Plaimauer, Barbara
    Rottensteiner, Hanspeter
    Gritsch, Herbert
    Federti, Enrica
    Matte, Alessandro
    De Franceschi, Lucia
    Scheiflinger, Friedrich
    Hoellriegl, Werner
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (02) : 269 - 275
  • [45] Recombinant ADAMTS13 efficacy to overwhelm inhibiting anti-ADAMTS13 autoantibody in acquired TTP patient plasma
    Plaimauer, B.
    Skalicky, S.
    Hasslacher, M.
    Wolfsegger, M.
    Scheiflinger, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 59 - 59
  • [46] ADAMTS13 antigen, activity, autoantibody and ADAMTS13/fXI complex levels may be useful diagnostic biomarkers for patients with sickle cell disease
    Fryer, Hugh J. L.
    Grafos, Nicholas
    Guinto, Enriqueta R.
    Wu, Jogin
    Bai, Bing
    Greenfield, Robert S.
    BLOOD, 2007, 110 (11) : 18B - 19B
  • [47] von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem-cell transplantation
    Kentouche, K
    Zintl, F
    Angerhaus, D
    Fuchs, D
    Hermann, J
    Schneppenheim, R
    Budde, U
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (02): : 98 - 104
  • [48] A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13
    Schiviz, Alexandra
    Wuersch, Kuno
    Piskernik, Christina
    Dietrich, Barbara
    Hoellriegl, Werner
    Rottensteiner, Hanspeter
    Scheiflinger, Friedrich
    Schwarz, Hans Peter
    Muchitsch, Eva-Maria
    BLOOD, 2012, 119 (25) : 6128 - 6135
  • [49] Correction of ADAMTS13 Deficiency by AAV-Mediated Gene Transfer of a C-Terminal Truncated ADAMTS13 Variant In a Murine Model
    Jin, Sheng-Yu
    Xiao, Juan
    Wright, J. Fraser
    Zheng, X. Long
    BLOOD, 2010, 116 (21) : 115 - 115
  • [50] Decreased ADAMTS13 Levels in Patients after Living Donor Liver Transplantation
    Kobayashi, Toshihiko
    Wada, Hideo
    Usui, Masanobu
    Sakurai, Hiroyuki
    Matsumoto, Takeshi
    Nobori, Tsutomu
    Katayama, Naoyuki
    Uemoto, Sinji
    Ishizashi, Hiromichi
    Matsumoto, Masanori
    Fujimura, Yoshihiro
    Isaji, Shuji
    THROMBOSIS RESEARCH, 2009, 124 (05) : 541 - 545
12345